PulseSight Therapeutics has completed dosing in its Phase 1 clinical [...]
SeaBeLife, a biotechnology company developing novel drug candidates to block [...]
Dosing of CPV-104 in healthy volunteers marks key milestone in [...]
PulseSight Therapeutics has completed dosing in its Phase 1 clinical [...]
SeaBeLife, a biotechnology company developing novel drug candidates to block [...]
Dosing of CPV-104 in healthy volunteers marks key milestone in [...]